FDA Clearance Tracker · P230011-S006
TruSight Oncology Comprehensive
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 14, 2026
Approved
Time to decision
269 days
Received Nov 18, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P230011-S006
- Device name
- TruSight Oncology Comprehensive
- Applicant
- Illumina, Inc.
- Applicant location
- San Diego, CA
- Received
- Nov 18, 2025
- Decided
- Aug 14, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P230011
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to expand the intended use of the TruSight Oncology Comprehensive to include a companion diagnostic indication to identify RET fusions in thyroid cancer (TC) patients and RET small DNA variant mutations in medullary thyroid cancer (MTC) patients who may benefit from treatment with RETEVMO® (selpercatinib).
Source documents
Other decisions for Illumina, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P230011 · Decided Aug 21, 2024 · 520 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.